Zymeworks Inc.
Zymeworks Inc.（ZYME）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · ZYME · 截至 2026年6月8日
活动摘要
买入笔数
0
P-Purchase only
卖出笔数
10
近12个月
买卖比
0.00
Buy/Sell (by trades)
整体情绪
Zymeworks Inc.内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月8日
ZYME 季度内部人买卖趋势
ZYME 内幕交易卖出 · ZYME 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 8, 2026
活跃内部人
近12个月交易最活跃 · ZYME CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
ZYME 高管卖出股份 · ZYME 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Jan 12, 2026 | Hollywood Mark EVP & Chief Operating Officer | Option | 17,666 | — | Form 4 |
| Jan 12, 2026 | Hollywood Mark EVP & Chief Operating Officer | Sale | 6,120 | $139K | Form 4 |
| Jan 12, 2026 | Smith Jeffrey T L EVP & Chief Medical Officer | Option | 17,666 | — | Form 4 |
| Jan 12, 2026 | Smith Jeffrey T L EVP & Chief Medical Officer | Sale | 9,310 | $211K | Form 4 |
| Jan 12, 2026 | Moore Paul Andrew Chief Scientific Officer | Option | 17,666 | — | Form 4 |
| Jan 12, 2026 | Moore Paul Andrew Chief Scientific Officer | Sale | 9,560 | $217K | Form 4 |
| Jan 12, 2026 | Galbraith Kenneth Chair & CEO · Director | Option | 64,000 | — | Form 4 |
| Jan 12, 2026 | Galbraith Kenneth Chair & CEO · Director | Sale | 30,424 | $690K | Form 4 |
| Jan 6, 2026 | PATTERSON LEONE D EVP, Chief Bus & Fin Officer | Award | 459 | $5K | Form 4 |
| Jan 5, 2026 | Smith Jeffrey T L EVP & Chief Medical Officer | Option | 20,000 | — | Form 4 |
| Jan 5, 2026 | Smith Jeffrey T L EVP & Chief Medical Officer | Sale | 10,538 | $264K | Form 4 |
| Jan 5, 2026 | Galbraith Kenneth Chair & CEO · Director | Option | 66,666 | — | Form 4 |
| Jan 5, 2026 | Galbraith Kenneth Chair & CEO · Director | Sale | 31,686 | $795K | Form 4 |
| Jan 5, 2026 | Galbraith Kenneth Chair & CEO · Director | Option | 47,668 | — | Form 4 |
| Jan 5, 2026 | Galbraith Kenneth Chair & CEO · Director | Sale | 22,657 | $569K | Form 4 |
| Jan 5, 2026 | Moore Paul Andrew Chief Scientific Officer | Option | 20,000 | — | Form 4 |
| Jan 5, 2026 | Moore Paul Andrew Chief Scientific Officer | Option | 17,168 | — | Form 4 |
| Jan 5, 2026 | Moore Paul Andrew Chief Scientific Officer | Sale | 10,821 | $272K | Form 4 |
| Jan 5, 2026 | Moore Paul Andrew Chief Scientific Officer | Sale | 9,289 | $233K | Form 4 |
| Dec 22, 2025 | Galbraith Kenneth Chair & CEO · Director | Option | 100,000 | — | Form 4 |
| Dec 22, 2025 | Galbraith Kenneth Chair & CEO · Director | Sale | 47,528 | $1.28M⚡ | Form 4 |
| Aug 12, 2025 | Ciongoli Gregory Austin Director | Award | 415,000 | $4.99M⚡ | Form 4 |
| Jun 26, 2025 | EcoR1 Capital, LLC Director | Other | 5,086,480 | $509 | Form 4 |
| Jun 26, 2025 | EcoR1 Capital, LLC Director | Other | 41 | $521 | Form 4 |
| May 19, 2025 | EcoR1 Capital, LLC Director | Purchase | 5,919 | $70K | Form 4 |
Hollywood Mark
EVP & Chief Operating Officer
日期
Jan 12
股数
6,120
均价
$22.67
总金额
$139K
Smith Jeffrey T L
EVP & Chief Medical Officer
日期
Jan 12
股数
9,310
均价
$22.67
总金额
$211K
Smith Jeffrey T L
EVP & Chief Medical Officer
日期
Jan 5
股数
10,538
均价
$25.10
总金额
$264K
Galbraith Kenneth
Chair & CEO · Director
日期
Dec 22
股数
47,528
均价
$27.02
总金额
$1.28M ⚡
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 ZYME 内幕交易
ZYME 内幕交易
Zymeworks Inc.（ZYME）内幕交易数据来源于公司内部人（包括Galbraith Kenneth (Chair & CEO · Director), Moore Paul Andrew (Chief Scientific Officer), Smith Jeffrey T L (EVP & Chief Medical Officer)）提交的SEC Form 4申报文件。过去12个月内，5位内部人向SEC提交了交易申报。ZYME内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Zymeworks Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
ZYME 内幕交易 · 5个问题Zymeworks Inc.（ZYME）的内部人包括高管和董事，如Galbraith Kenneth (Chair & CEO · Director), Moore Paul Andrew (Chief Scientific Officer), Smith Jeffrey T L (EVP & Chief Medical Officer)等。过去12个月内，5位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 8, 2026